Outcomes of three intravitreal injections of bevacizumab given monthly for diabetic macular oedema is a viable treatment for an economically disadvantaged population
Background: The treatment of diabetic macular oedema (DMO) by intravitreal injection (IVI) of approved anti-vascular endothelial growth factor (VEGF) is costly and hence off label use of bevacizumab is practiced in spite of concerns about its safety. Aim: To examine the effect of three IVI of bevac...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2021-04-01
|
| Series: | African Vision and Eye Health |
| Subjects: | |
| Online Access: | https://avehjournal.org/index.php/aveh/article/view/618 |